Open AccessROLE OF FAVIPIRAVIR IN COVID-19: A REVIEW
Author(s) -
Dhanashree Rajhans,
Manali Atre
Publication year - 2020
Publication title -
international journal of engineering applied science and technology
Language(s) - English
Resource type - Journals
ISSN - 2455-2143
DOI - 10.33564/ijeast.2020.v05i04.086
Subject(s) - favipiravir , covid-19 , virology , betacoronavirus , medicine , outbreak , disease , infectious disease (medical specialty)
An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been reported in China since December 2019. Recent global outbreak of the pandemic caused by coronavirus emphasizes the urgent need for novel antiviral therapeutics. Covid-19 infection caused by the novel coronavirus SARS-COV-2 continues to be a major global health challenge. A number of medications have been proposed and there are ongoing clinical trials around the world to search a suitable treatment. Herein, we reviewed the effects of Favipiravir for the treatment of COVID-19. This review elaborates the mechanism of action, development, pharmacokinetics and details of clinical trials for Favipiravir to be beneficial and actively involved in controlling the pandemic and to provide therapeutics for the treatment of COVID-19 infection. Favipiravir shows better therapeutic responses on COVID-19 in terms of disease evolution and viral clearance. The preliminary clinical results provide useful information of treatments for SARS-CoV-2 infection. Favipiravir may be safe and tolerable in short-term use, but further evidence is needed to assess the longe-term effects of treatment. Keywords— COVID-19, Favipiravir, clinical trials.